Lack of QT Prolongation for 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlle...

por Yu, Rosie Z., Gunawan, Rudy, Geary, Richard S., Hughes, Steven G., Henry, Scott P., Wang, Yanfeng
Publicado 2017

Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience

por Crooke, Stanley T., Baker, Brenda F., Xia, Shuting, Yu, Rosie Z., Viney, Nicholas J., Wang, Yanfeng, Tsimikas, Sotirios, Geary, Richard S.
Publicado 2019

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis

por Yu, Rosie Z., Collins, Jon W., Hall, Shannon, Ackermann, Elizabeth J., Geary, Richard S., Monia, Brett P., Henry, Scott P., Wang, Yanfeng
Publicado 2020

Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications

por Yu, Rosie Z, Grundy, John S, Henry, Scott P, Kim, Tae-Won, Norris, Daniel A, Burkey, Jennifer, Wang, Yanfeng, Vick, Andrew, Geary, Richard S
Publicado 2015

Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI(Rx) in Patients With ESRD

por Walsh, Michael, Bethune, Claudette, Smyth, Andrew, Tyrwhitt, Jessica, Jung, Shiangtung W., Yu, Rosie Z., Wang, Yanfeng, Geary, Richard S., Weitz, Jeffrey, Bhanot, Sanjay
Publicado 2021

Assessment of the Drug Interaction Potential of Unconjugated and GalNAc(3)-Conjugated 2′-MOE-ASOs

por Shemesh, Colby S., Yu, Rosie Z., Warren, Mark S., Liu, Michael, Jahic, Mirza, Nichols, Brandon, Post, Noah, Lin, Song, Norris, Daniel A., Hurh, Eunju, Huang, Jane, Watanabe, Tanya, Henry, Scott P., Wang, Yanfeng
Publicado 2017

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

por Willmann, Stefan, Marostica, Eleonora, Snelder, Nelleke, Solms, Alexander, Jensen, Markus, Lobmeyer, Maximilian, Lensing, Anthonie W. A., Bethune, Claudette, Morgan, Erin, Yu, Rosie Z., Wang, Yanfeng, Jung, Shiangtung W., Geary, Richard, Bhanot, Sanjay
Publicado 2021

Disposition and Pharmacology of a GalNAc(3)-conjugated ASO Targeting Human Lipoprotein (a) in Mice

por Yu, Rosie Z, Graham, Mark J, Post, Noah, Riney, Stan, Zanardi, Thomas, Hall, Shannon, Burkey, Jennifer, Shemesh, Colby S, Prakash, Thazha P, Seth, Punit P, Swayze, Eric E, Geary, Richard S, Wang, Yanfeng, Henry, Scott
Publicado 2016

Elucidation of the Biotransformation Pathways of a Galnac(3)-conjugated Antisense Oligonucleotide in Rats and Monkeys

por Shemesh, Colby S, Yu, Rosie Z, Gaus, Hans J, Greenlee, Sarah, Post, Noah, Schmidt, Karsten, Migawa, Michael T, Seth, Punit P, Zanardi, Thomas A, Prakash, Thazha P, Swayze, Eric E, Henry, Scott P, Wang, Yanfeng
Publicado 2016

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

por Viney, Nicholas J., Guo, Shuling, Tai, Li‐Jung, Baker, Brenda F., Aghajan, Mariam, Jung, Shiangtung W., Yu, Rosie Z., Booten, Sheri, Murray, Heather, Machemer, Todd, Burel, Sebastien, Murray, Sue, Buchele, Gustavo, Tsimikas, Sotirios, Schneider, Eugene, Geary, Richard S., Benson, Merrill D., Monia, Brett P.
Publicado 2020